{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:55:48Z","timestamp":1788317748683,"version":"build-2803163510"},"reference-count":32,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We examined the individual prognostic contribution of absolute neutrophil (ANC), lymphocyte (ALC), and monocyte (AMC) counts, on overall (OS), leukemia\u2010free (LFS), and myelofibrosis\u2010free (MFFS) survival in essential thrombocythemia (ET). Informative cases (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u2009598; median age 59\u2009years; females 62%) were retrospectively accrued from a Mayo Clinic database:\n                    <jats:italic>JAK2<\/jats:italic>\n                    59%,\n                    <jats:italic>CALR<\/jats:italic>\n                    27%, triple\u2010negative 11%, and\n                    <jats:italic>MPL<\/jats:italic>\n                    3%; international prognostic scoring system for ET (IPSET) risk high 21%, intermediate 42%, and low 37%; 7% (37\/515) had abnormal karyotype and 10% (21\/205) adverse mutations (\n                    <jats:italic>SF3B1\/SRSF2\/U2AF1\/TP53<\/jats:italic>\n                    ). At median 8.4\u2009years, 163 (27%) deaths, 71 (12%) fibrotic, and 20 (3%) leukemic transformations were recorded. Multivariable analysis resulted in HR (95% CI) of 16.5 (9.9\u201327.4) for age\u2009&gt;\u200970\u2009years, 3.7 (2.3\u20136.0) for age 50\u201370\u2009years, 2.4 (1.7\u20133.3) for ANC \u22658\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/L, and 1.9 (1.4\u20132.6) for ALC &lt;1.7\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/L. The corresponding HR\u2010based scores were 4, 2, 1, and 1, resulting in an new 4\u2010tiered AgeAncAlc (AAA; triple A) risk model: high (5\u20136 points; median survival 8\u2009years; HR 30.1, 95% CI 17.6\u201354), intermediate\u20102 (4 points; median 13.5\u2009years; HR 12.7, 95% CI 7.1\u201323.0), intermediate\u20101 (2\u20133 points; median 20.7\u2009years; HR 3.8, 95% CI 2.3\u20136.4) and low (0\u20131 points; median 47\u2009years). The AAA model (Akaike Information Criterion [AIC] 621) performed better than IPSET (AIC 647) and was subsequently validated by an external University of Florence ET cohort (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u2009485). None of the AAA variables predicted LFS while ALC &lt;1.7\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/L was associated with inferior MFFS (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u2009.01). Adverse mutations (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u2009.01) and karyotype (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u2009.01) displayed additional prognostic value without disqualifying the prognostic integrity of the AAA model. This study proposes a simple and globally applicable survival model for ET, which can be used as a platform for further molecular refinement. This study also suggests a potential role for immune\u2010related biomarkers, as a prognostic tool in myeloproliferative neoplasms.\n                  <\/jats:p>","DOI":"10.1002\/ajh.27079","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T14:14:10Z","timestamp":1693836850000},"page":"1829-1837","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["A globally applicable \u201ctriple\n                    <scp>A<\/scp>\n                    \u201d risk model for essential thrombocythemia based on\n                    <scp>A<\/scp>\n                    ge,\n                    <scp>A<\/scp>\n                    bsolute neutrophil count, and\n                    <scp>A<\/scp>\n                    bsolute lymphocyte count"],"prefix":"10.1002","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[{"name":"Divisions of Hematology and Hematopathology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6241-1206","authenticated-orcid":false,"given":"Giuseppe G.","family":"Loscocco","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, CRIMM, Center Research, and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi University of Florence  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiqa","family":"Farrukh","sequence":"additional","affiliation":[{"name":"Divisions of Hematology and Hematopathology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Szuber","sequence":"additional","affiliation":[{"name":"Department of Hematology Universit\u00e9 de Montr\u00e9al  Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4810-6501","authenticated-orcid":false,"given":"Francesco","family":"Mannelli","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, CRIMM, Center Research, and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi University of Florence  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9084-4148","authenticated-orcid":false,"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[{"name":"Divisions of Hematology and Hematopathology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[{"name":"Divisions of Hematology and Hematopathology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett P.","family":"Ketterling","sequence":"additional","affiliation":[{"name":"Divisions of Hematology and Hematopathology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-5827","authenticated-orcid":false,"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Radiological and Hematological Sciences Catholic University  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Carobbio","sequence":"additional","affiliation":[{"name":"FROM esearch Foundation Papa Giovanni XXIII Hospital  Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[{"name":"FROM esearch Foundation Papa Giovanni XXIII Hospital  Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, CRIMM, Center Research, and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi University of Florence  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[{"name":"Divisions of Hematology and Hematopathology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, CRIMM, Center Research, and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi University of Florence  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26751"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26821"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.89"},{"key":"e_1_2_9_6_1","first-page":"108","article-title":"Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival","volume":"13","author":"Abdelmagid MG","year":"2023","journal-title":"Haematologica"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0019-y"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1816082"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-579136"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.08.022"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25270"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-403279"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16380"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.4886"},{"key":"e_1_2_9_16_1","volume-title":"ISCN 2009: an International System for Human Cytogenetic Nomenclature (2009): recommendations of the International Standing Committee on Human Cytogenetic Nomenclature Basel","author":"Shaffer LG","year":"2009"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26448"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.30"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21618"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0223-7"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26090"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06232.x"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404780"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07123.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3845"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0151"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.16526"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26423"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00625-5"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.163"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23295"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23406"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.9490"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.27079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T05:08:16Z","timestamp":1711688896000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.27079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1002\/ajh.27079"],"URL":"https:\/\/doi.org\/10.1002\/ajh.27079","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]},"assertion":[{"value":"2023-08-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}